Drug intelligence / Profile preview

bangruitinib

Development stage: Unknown
Lead developer: Huadong Medicine
Modality: Small Molecules
Administration: Oral

Overview

Bangruitinib (also known as HD-001) is an orally bioavailable small molecule inhibitor of Janus kinase 2 (JAK2) developed by Hangzhou Huadong Medicine Group Biopharmaceutical. It is primarily being investigated for the treatment of myeloproliferative neoplasms (MPNs), specifically polycythemia vera (PV) and myelofibrosis. The drug targets the JAK-STAT signaling pathway, which is frequently dysregulated in MPNs due to mutations such as JAK2 V617F, leading to the overproduction of blood cells. Bangruitinib is currently in Phase 3 clinical trials in China for patients with PV who are resistant or intolerant to hydroxyurea, aiming to provide a therapeutic alternative for patients who have failed standard frontline therapy.

Other names: 邦瑞替尼

Targets

JAK2 (Janus kinase 2)

Beyond the preview

Go deeper on bangruitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bangruitinib.

Explore the full profile